NCT06555068
A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid Tumors
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 5 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 31 words
- Interventions modified
- Trial arms changed: 9 → 13
- Study title expanded, about 8 words
Notable Primary completion date: Dec 2025 to Dec 2027v6 Show 5 more changesShow less
- Eligibility criteria expanded, about 64 words
- Study completion date: Aug 2026 to Aug 2028
- Interventions: HRS-6209 in Combination with Fulvestrant (Drug), HRS-6209 in Combination with HRS-1358 (Drug), HRS-6209 in Combination with HRS-1358… to HRS-6209 in Combination with Fulvestrant (Drug), HRS-6209 in Combination with HRS-1358 (Drug), HRS-6209 in Combination with HRS-1358…
- Secondary endpoints: details revised at 8 of 18 entries
- Study arms: 5 to 9
- Notable Eligibility criteria expanded, about 5 wordsv4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Aug 2024 to Aug 12, 2024
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (18)
Show 13 moreShow less
Arms and interventions
Drugs: HRS-6209 in Combination with Fulvestrant, HRS-6209 in Combination with HRS-1358, HRS-6209 in Combination with Letrozole, HRS-6209 in Combination with HRS-8080, HRS-6209 in Combination with HRS-9813 and Letrozole, HRS-6209 in Combination with HRS-9813 and HRS-8080, HRS-6209 in Combination with letrozole and trastuzumab, HRS-6209 in Combination with letrozole and trastuzumab and pertuzumab, HRS-6209 in Combination HRS-4508 and letrozole, HRS-6209 in Combination HRS-4508 and letrozole and trastuzumab and pertuzumab
Sites
1 site in 1 country
- Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality, China